A balloon catheter is disclosed capable of effectively delivering a drug to living body tissue and a manufacturing method of the balloon catheter, and a treatment method. The balloon catheter has a balloon at a distal portion of a catheter shaft, and is provided on a surface of the balloon with elongate bodies which are crystals of a water-insoluble drug extending in a longitudinal direction. The surface of the balloon is provided with crystal conjugates formed of a plurality of elongate bodies united to one another while being in a tilted state.

Angioplasty balloons coated with at least one limus drug, which may be in crystalline form, optionally with at least one excipient, and methods for manufacturing such coated angioplasty balloons.

A balloon catheter that includes an elongated main body extending in an axial direction and a balloon connected to the distal portion of the elongated main body. The balloon includes an interior and is inflatable and deflatable. The balloon catheter also includes a plurality of elongate bodies extending radially away from the outer surface of the balloon. The elongate bodies are crystals of a water-insoluble drug. The elongate bodies each possess an independent longitudinal axis. Each of the elongate bodies includes a base portion at the proximal end of the elongate body. A plurality of elongate body proximal portions extend radially inwardly from the base portion of each of the elongate bodies toward the interior of the balloon. The elongate body proximal portions are continuous extensions of the crystal of the water-insoluble drug.

Collagen matrix granulate blend, and process for making and using a collagen matrix or granulate blend including collagen and particles of a biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material having a sintered CAP core and having its total external surface covered by at least one closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, wherein the closed epitactically grown layer of nanocrystalline HAP is transformed from the CAP on the external surface of the sintered CAP core has a non-homogeneous external surface comprising individual clusters of flat crystal platelets consisting of epitactically grown HAP nanocrystals and coarse areas between the individual clusters, whereby the percentage of the coarse areas between the individual clusters as measured by SEM is at least 20% of the total surface.

Provided is a stent comprising: a stent skeleton; and a deposition layer containing a plurality of layers deposited on the stent skeleton; each layer of the deposition layer comprising crystalline cilostazol, at least one of the plurality of layers comprising a bioabsorbable polymer, wherein elution of not more than 5% by mass of the crystalline cilostazol occurs by 24 hours after the stent is brought into contact in vitro at 37° C. with an elution medium of a phosphate-buffered sodium chloride solution containing 0.25% by mass of sodium lauryl sulfate.

A balloon catheter is disclosed having a balloon at a distal portion of a catheter shaft and on a surface of the balloon are elongate bodies which are crystals of a water-insoluble drug having independent long axes. The balloon in a deflated state has a plurality of wing portions in a circumferential direction of the balloon, and a circumferential surface portion along a circumferential direction of the catheter shaft, the plurality of wing portions being folded along the circumferential direction of the balloon. A surface of the circumferential surface portion which faces the plurality of wing portions that are folded has a region in which tip portions are not in contact with the surface of the balloon or with other elongate bodies, and a surface which faces the plurality of wing portions that are folded which faces an outer circumferential side has a region in which the tip portions are in contact with the surface of the balloon or with the other elongate bodies.

Angioplasty balloons coated with at least one limus drug, which may be in crystalline form, optionally with at least one excipient, and methods for manufacturing such coated angioplasty balloons.

The present disclosure is directed toward composite materials comprising high aspect ratio habits of drug crystals which can be partially or fully extending into a substrate, and additionally, can be projecting from a substrate at an angle of about 20° to about 90°. The present disclosure is directed toward medical devices, such as medical balloons, comprising said composite and methods of using and making the same. The described composite can be used for the local treatment of vascular disease. The present disclosure is also directed toward paclitaxel crystals with a hollow acicular habit.

In order to provide medical devices having a coating for local prophylaxis and treatment of undesirable cell proliferation and vasoconstriction, a medical device comprising a coating on at least a portion of the surface is proposed, said coating comprising at least one limus substance in non-encapsulated crystalline form, wherein the at least one non-encapsulated limus substance is applied directly from a solvent mixture of at least one organic solvent and water. The formation of crystals of the limus substance can be brought about or enhanced by slowing down the evaporation of the solvent mixture.

In addition, a method for preparing the medical devices is proposed.

Provided is a stent comprising: a stent skeleton; and a deposition layer containing a plurality of layers deposited on the stent skeleton; each layer of the deposition layer comprising crystalline cilostazol, at least one of the plurality of layers comprising a bioabsorbable polymer, wherein elution of not more than 5% by mass of the crystalline cilostazol occurs by 24 hours after the stent is brought into contact in vitro at 37° C. with an elution medium of a phosphate-buffered sodium chloride solution containing 0.25% by mass of sodium lauryl sulfate.